JP2023554046A5 - - Google Patents
Info
- Publication number
- JP2023554046A5 JP2023554046A5 JP2023536144A JP2023536144A JP2023554046A5 JP 2023554046 A5 JP2023554046 A5 JP 2023554046A5 JP 2023536144 A JP2023536144 A JP 2023536144A JP 2023536144 A JP2023536144 A JP 2023536144A JP 2023554046 A5 JP2023554046 A5 JP 2023554046A5
- Authority
- JP
- Japan
- Prior art keywords
- diacid
- cntatc
- amide
- aib
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025182255A JP2026031965A (ja) | 2020-12-16 | 2025-10-29 | ポリペプチド及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125996P | 2020-12-16 | 2020-12-16 | |
| US63/125,996 | 2020-12-16 | ||
| PCT/EP2021/086034 WO2022129254A1 (en) | 2020-12-16 | 2021-12-15 | Polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025182255A Division JP2026031965A (ja) | 2020-12-16 | 2025-10-29 | ポリペプチド及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023554046A JP2023554046A (ja) | 2023-12-26 |
| JP2023554046A5 true JP2023554046A5 (https=) | 2024-10-24 |
| JP7767428B2 JP7767428B2 (ja) | 2025-11-11 |
Family
ID=79287870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536144A Active JP7767428B2 (ja) | 2020-12-16 | 2021-12-15 | ポリペプチド及びその使用 |
| JP2025182255A Pending JP2026031965A (ja) | 2020-12-16 | 2025-10-29 | ポリペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025182255A Pending JP2026031965A (ja) | 2020-12-16 | 2025-10-29 | ポリペプチド及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US12371464B2 (https=) |
| EP (2) | EP4736944A2 (https=) |
| JP (2) | JP7767428B2 (https=) |
| KR (1) | KR20230120134A (https=) |
| CN (1) | CN116685599A (https=) |
| AR (1) | AR124391A1 (https=) |
| AU (2) | AU2021399076B2 (https=) |
| CA (1) | CA3204296A1 (https=) |
| CL (1) | CL2023001719A1 (https=) |
| CO (1) | CO2023009066A2 (https=) |
| CR (1) | CR20230311A (https=) |
| EC (1) | ECSP23052600A (https=) |
| IL (1) | IL303578A (https=) |
| MX (1) | MX2023007288A (https=) |
| TW (1) | TW202241933A (https=) |
| WO (1) | WO2022129254A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20230311A (es) | 2020-12-16 | 2023-09-01 | Medimmune Ltd | Polipéptidos y usos de los mismos |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| IL322661A (en) * | 2023-02-10 | 2025-10-01 | Hangzhou Sciwind Biosciences Co Ltd | Polypeptide and its history, composition containing them and their use |
| TW202540155A (zh) | 2023-11-30 | 2025-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
| WO2025147628A2 (en) * | 2024-01-05 | 2025-07-10 | Indiana University Research And Technology Corporation | Dual amylin calcitonin receptor agonists |
| WO2025242620A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Polypeptide combinations and uses thereof |
| WO2026058194A1 (en) | 2024-09-12 | 2026-03-19 | Medimmune Limited | Polypeptide dosage regimens |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004051014A1 (de) * | 2004-10-20 | 2006-04-27 | Rwth Aachen | Chemisch modifizierte Peptidanaloga |
| JP5252435B2 (ja) * | 2006-03-15 | 2013-07-31 | ノボ・ノルデイスク・エー／エス | アミリン誘導体 |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| ES2662501T3 (es) * | 2008-10-21 | 2018-04-06 | Novo Nordisk A/S | Derivados de amilina |
| US9205135B2 (en) * | 2009-09-22 | 2015-12-08 | University Of Miami | Podocyte pH modulation and uses thereof |
| US20140249076A1 (en) | 2011-10-18 | 2014-09-04 | Astrazeneca Pharmaceuticals Lp | Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties |
| CN105849123A (zh) * | 2013-12-13 | 2016-08-10 | 免疫医疗有限公司 | 蛋白酶抗性肽 |
| JP6730278B2 (ja) * | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| AR116632A1 (es) * | 2018-10-11 | 2021-05-26 | Intarcia Therapeutics Inc | Polipéptidos análogos de la amilina humana y sus métodos de uso |
| WO2020225781A1 (en) * | 2019-05-08 | 2020-11-12 | Auckland Uniservices Limited | Peptide conjugate amylin agonists and uses thereof |
| CR20230311A (es) | 2020-12-16 | 2023-09-01 | Medimmune Ltd | Polipéptidos y usos de los mismos |
-
2021
- 2021-12-15 CR CR20230311A patent/CR20230311A/es unknown
- 2021-12-15 MX MX2023007288A patent/MX2023007288A/es unknown
- 2021-12-15 IL IL303578A patent/IL303578A/en unknown
- 2021-12-15 CA CA3204296A patent/CA3204296A1/en active Pending
- 2021-12-15 US US17/551,701 patent/US12371464B2/en active Active
- 2021-12-15 EP EP26151626.4A patent/EP4736944A2/en active Pending
- 2021-12-15 KR KR1020237023385A patent/KR20230120134A/ko active Pending
- 2021-12-15 AU AU2021399076A patent/AU2021399076B2/en active Active
- 2021-12-15 US US18/257,756 patent/US20240067693A1/en active Pending
- 2021-12-15 CN CN202180084231.3A patent/CN116685599A/zh active Pending
- 2021-12-15 WO PCT/EP2021/086034 patent/WO2022129254A1/en not_active Ceased
- 2021-12-15 EP EP21839935.0A patent/EP4263586B1/en active Active
- 2021-12-15 JP JP2023536144A patent/JP7767428B2/ja active Active
- 2021-12-16 TW TW110147305A patent/TW202241933A/zh unknown
- 2021-12-16 AR ARP210103535A patent/AR124391A1/es unknown
-
2023
- 2023-06-14 CL CL2023001719A patent/CL2023001719A1/es unknown
- 2023-07-06 CO CONC2023/0009066A patent/CO2023009066A2/es unknown
- 2023-07-12 EC ECSENADI202352600A patent/ECSP23052600A/es unknown
-
2024
- 2024-10-03 AU AU2024227071A patent/AU2024227071A1/en active Pending
-
2025
- 2025-02-12 US US19/052,168 patent/US20250289860A1/en active Pending
- 2025-10-29 JP JP2025182255A patent/JP2026031965A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023554046A5 (https=) | ||
| US12054528B2 (en) | Co-agonists of the GLP-1 and amylin receptors | |
| JP2008500281A5 (https=) | ||
| EP2729493B1 (en) | Novel compounds and their effects on feeding behaviour | |
| TWI428346B (zh) | 新穎化合物及其等對進食行為影響 | |
| US8114958B2 (en) | Amylin family peptides | |
| JP7767428B2 (ja) | ポリペプチド及びその使用 | |
| CA2310097C (en) | Novel exendin agonist compounds | |
| CA2320371A1 (en) | Inotropic and diuretic effects of exendin and glp-1 | |
| US20110230409A1 (en) | GLP-I Agonist And Cardiovascular Complications | |
| WO2021136293A1 (zh) | 胰岛素衍生物 | |
| EP2468858A1 (en) | Fusion protein regulating plasma glucose and lipid, its preparation method and use | |
| JP2019504055A5 (https=) | ||
| TW200848423A (en) | Glucagon/GLP-1 receptor co-agonists | |
| WO2017181452A1 (zh) | Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化 | |
| EP1263458A1 (en) | Lowering serum lipids | |
| EP3442997A2 (en) | Fgf21 c-terminal peptide optimization | |
| CN101578107B (zh) | 泌酸调节肽类似物及其对进食行为的影响 | |
| US20080280815A1 (en) | Lowering Serum Lipids | |
| AU2024335696A1 (en) | Stable glp-1 analogs for the treatment of human disease and disorders | |
| RU2025125845A (ru) | Соединения | |
| CN121991202A (zh) | Glp-1和胰淀素受体的共激动剂 | |
| GB2642930A (en) | Compounds | |
| CN121975020A (en) | Co-agonists of GLP-1 and the amylin receptor | |
| BR122024023347A2 (pt) | Coagonistas dos receptores glp-1 e amilina, formulação farmacêutica compreendendo os ditos coagonistas e uso terapêutico dos mesmos |